Clinical TrialsClinically meaningful and statistically significant improvements in key efficacy measures were observed in the Phase 2 trial, supporting the potential success of the Phase 3 trial.
Financial PositionPVLA's cash position is sufficient to fund operations well into the future, supporting ongoing and new developments.
Regulatory SupportQTORIN rapamycin has Breakthrough Therapy Designation, Fast Track Designation, and Orphan Drug Designation, and should be eligible for Priority Review.